Table 1.
Patient Characteristics
| Study Subjects with Early HIV-1 Infection | ||
|---|---|---|
| Participant | Viral Load (copies/ml) | Weeks after Enrollment |
| AC255 | 439 | 29 |
| AC253 | 1440 | 25 |
| AC259 | 3550 | 10 |
| AC258 | 5590 | 14 |
| AC260 | 15,800 | 15 |
| AC277 | 29,100 | 5 |
| AC270 | 32,300 | 2 |
| AC246 | 46,200 | 40 |
| AC264 | 88,100 | 29 |
| AC248 | 124,000 | 28 |
| AC278 | 640,000 | 0 |
| AC267 | 5,710,000 | 2 |
| Study Subjects in Structured Treatment Interruption Trial | |||
|---|---|---|---|
| Participant | No. of Interruptions | Viral Load at Initiation of ARVs During Acute Infection | CD4 Count at Initiation of ARVs |
| AC-10 | 1 | 40,700 | 919 |
| AC-15 | 1 | 27,000 | 413 |
| AC-45 | 1 | 2,090,000 | 377 |
| AC-02 | 2 | 4,850,000 | NA |
| AC-16 | 2 | 337,000 | NA |
| AC-13 | 2 | 5500 | 667 |
| AC-33 | 2 | 26,700 | 512 |
| AC-14 | 3 | 95,100 | 981 |
| AC-25 | 3 | 697,000 | 314 |
| AC-26 | 3 | 1,260,000 | 390 |
| AC-46 | 3 | 123,000 | NA |
| AC-04 | 4 | 9,620,000 | NA |
| AC-05 | 4 | 1,100,000 | 289 |
| AC-06 | 4 | 8,180,000 | 551 |